Royalty Pharma PLC
MEX : RPRXNMX$1,025.44+0.00%latest daily quote
Financials
Income statement · full history
USD in millions · per-share amounts unscaled. Each period shows the value from the latest filing that prints it.
| Reported line item | Jan 1, 2018 to Dec 31, 2018 | Jan 1, 2019 to Dec 31, 2019 | Jan 1, 2020 to Dec 31, 2020 | Jan 1, 2021 to Dec 31, 2021 | Jan 1, 2022 to Dec 31, 2022 | Jan 1, 2023 to Dec 31, 2023 | Jan 1, 2024 to Dec 31, 2024 | Jan 1, 2025 to Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Total income and other revenues | 1,794.89 | 1,814.25 | 2,122.35 | 2,289.46 | 2,237.22 | 2,354.55 | 2,263.58 | 2,378.19 |
| Provision for changes in expected cash flows from financial royalty assets | (57.33) | (1,019.32) | 230.84 | 452.84 | 904.24 | 560.66 | 732.46 | (295.84) |
| Provision for credit losses on unfunded commitments | 0 | 0 | 89.03 | |||||
| Research and development funding expense | 392.61 | 83.04 | 26.29 | 200.08 | 177.11 | 52 | 2 | 452 |
| General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4) | 61.91 | 103.44 | 181.72 | 182.83 | 227.3 | 249.75 | 236.67 | 573.48 |
| Amortization of intangible assetsno longer reported | 33.27 | 23.92 | 23.06 | 23 | 5.67 | 0 | 0 | |
| Total operating expense, net | 430.45 | (808.92) | 526.95 | 858.75 | 1,930.15 | 862.4 | 971.13 | 818.68 |
| Financial royalty asset impairmentno longer reported | 65.05 | 0 | 615.83 | 0 | 0 | |||
| Other operating expensesno longer reported | 0 | 0 | 65.05 | 0 | ||||
| Operating income | 1,364.45 | 2,623.18 | 1,595.4 | 1,430.72 | 307.07 | 1,492.15 | 1,292.44 | 1,559.52 |
| Equity in earnings of equity method investees | 7.02 | 32.52 | (44.46) | 19.49 | 8.97 | (28.88) | (29.61) | (29.09) |
| Interest expense | 279.96 | 268.57 | 157.06 | 166.14 | 187.96 | 187.19 | 225.51 | 307.66 |
| Losses on derivative financial instruments | (11.92) | 39.14 | 42.08 | 21.53 | (96.61) | 2.29 | 6 | 0 |
| Realized gain on available for sale debt securitiesno longer reported | (419.48) | 0 | 0 | |||||
| Losses/(gains) on equity securities | 13.94 | (155.75) | (247.07) | 48.07 | 33.44 | (87.14) | (39.55) | 21.85 |
| Gains on available for sale debt securities | 0 | (18.6) | (17.86) | 6.82 | (230.84) | (154.91) | (45.86) | |
| Unrealized Gain (Loss) on Derivativesno longer reported | 0 | 0 | (18.6) | |||||
| Interest income | (24.44) | (22.33) | (28.38) | (53.54) | (78.34) | (72.29) | (47.34) | (33.59) |
| Other non-operating expenses, net | 1.52 | (0.39) | 32.82 | 5.68 | 14.76 | 21.74 | 1.53 | 14.35 |
| Total other expense/(income), net | (153.41) | 161.76 | (106.56) | 189.51 | 77 | (207.94) | (38.37) | 235.33 |
| Consolidated net income before tax | 1,517.86 | 2,461.42 | 1,701.95 | 1,241.2 | 230.06 | 1,700.09 | 1,330.81 | 1,324.19 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Consolidated net income | 1,517.86 | 2,461.42 | 1,701.95 | 1,241.2 | 230.06 | 1,700.09 | 1,330.81 | 1,324.19 |
| Net income attributable to non-controlling interests | (140.13) | 112.88 | 726.91 | 621.47 | 187.23 | 565.25 | 471.83 | 553.25 |
| Net income attributable to Royalty Pharma plc | 1,377.73 | 2,348.54 | 975.04 | 619.73 | 42.83 | 1,134.83 | 858.98 | 770.95 |
| Basic (in dollars per share) | — | — | 1.32 | 1.49 | 0.10 | 2.54 | 1.92 | 1.79 |
| Reclassification of loss on interest rate swapsno longer reported | 8 | 6.19 | 4.07 | |||||
| Diluted (in dollars per share) | — | — | 1.32 | 1.49 | 0.10 | 2.53 | 1.91 | 1.78 |
| Unrealized gain/(loss) on available for sale debt securitiesno longer reported | (402.5) | 6.16 | 83.12 | |||||
| Basic (in shares) | — | — | 375.44 | 414.79 | 437.96 | 447.6 | 448.19 | 429.8 |
| Reclassification of unrealized gain on available for sale debt securitiesno longer reported | 0 | 0 | (20.55) | |||||
| Diluted (in shares) | — | — | 375.46 | 414.8 | 437.97 | 602.9 | 594.11 | 564.46 |
| Other comprehensive income/(loss)no longer reported | (394.5) | 12.35 | 66.64 | |||||
| Comprehensive incomeno longer reported | 983.23 | 2,360.88 | 1,041.68 | |||||
| Less: Other comprehensive income attributable to non-controlling interestno longer reported | 0 | 0 | (12.87) | |||||
| Comprehensive income attributable to controlling interestno longer reported | 983.23 | 2,360.88 | 1,028.8 |
History starts FY2018, the period ended Dec 31, 2018 — the earliest period our structured-data source covers, not the company’s first year.
36 reported lines · 8 periods · values taken from the latest filing that prints each period.
- italic24 from an earlier filing than the rest of the column.
- no longer reported12 lines the filer stopped printing.
- — the filer printed the line and left the period empty. An empty cell means the line was not printed at all; it is never a zero.
221 of 221 values link to the exact element in the filer’s own document.
Every line and every caption is the company’s own. Each period carries the value from the latest filing that prints it, which is why a restated period shows the restated number with the figure as first reported kept underneath.
Nothing on this table is computed by us: no fourth quarter, no growth rate, no margin. Marks describe the filer’s own restatements.